GCC Biosimilar Market Overview:
The GCC biosimilar market was worth US$ XX Billion in 2021, expanding at a CAGR of X% during 2016-2021. The market is projected to register a CAGR of X% during 2022-2027, reaching US$ XX Billion by 2027. A biosimilar, also known as a follow-on drug, refers to a biopharmaceutical drug that is highly similar to a reference biologic drug in terms of safety, quality, and efficacy. It can only be manufactured after the patent of the reference product has expired. It is produced using biological substances, such as microorganisms and plant or animal cells. It is widely used to prevent, determine and treat various medical conditions and manufacture vaccines, therapeutic proteins, and monoclonal antibodies. In recent years, biosimilar drugs have gained traction across the GCC region as they are effective for medical use with no clinically significant differences.
The GCC biosimilar market is primarily driven by the rising number of patent expiration of blockbuster biologic drugs. Additionally, the widespread prevalence of chronic conditions, such as cancer, diabetes, and autoimmune diseases, has augmented the demand for biosimilar drugs as they are more cost-effective than their branded counterparts. Furthermore, governments of various GCC countries are taking several initiatives to promote the production and usage of biosimilar drugs. Along with this, the introduction of favorable policies to accelerate the approvals of biosimilar drugs has propelled the market growth. Other factors, including the rising geriatric population, increasing investments toward the development of healthcare infrastructure, rapid urbanization, and easy product availability, are also anticipated to catalyze the market growth.
GCC Biosimilar Market Segment Insights:
The report has assessed the GCC biosimilar market on the basis of molecule covering, infliximab, insulin glargine, epoetin alfa, etanercept, filgrastim, somatropin, rituximab and follitropin alfa. The report has further examined the market based on type of manufacturing including, In-house manufacturing and contract manufacturing. On the basis of indication covering, auto-immune diseases, blood disorder, diabetes, oncology, growth deficiency and female infertility. On a regional basis, the report examines the biosimilar market in Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Oman and Bahrain. An evaluation of the competitive landscape has also been provided with the details of the key players operating in the GCC biosimilar market.
Highlights of the GCC Biosimilar Market Report:
Key Market Segments:
The GCC biosimilar market has been analysed as followed:
Segmentation by Molecule:
Segmentation by Type of Manufacturing:
Segmentation by Indication:
Segmentation by Country:
Report Customisation:
The GCC biosimilar market report can be customised as per your requirements. You can get in touch with our analyst, who will make sure that the report suits your research needs
1 Introduction
1.1 Research Objectives
1.2 Stakeholders
1.3 Scope of the Report
1.4 Assumptions and Limitations
2 Research Methodology
2.1 Data Collection
2.1.1 Primary Sources
2.1.2 Secondary Sources
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Data Validation
3 Executive Summary
4 Introduction to Global Biosimilar Market
4.1 Overview
4.2 WHO and FDA Terminology on Biosimilars
4.3 Biosimilars and Generics
4.3 Biosimilars and Branded Biological Products
5 Biosimilar Research, Development and Manufacturing
5.1 Research and Development: Biosimilars vs. Innovator Drugs
5.2 Manufacturing: Biosimilars vs. Innovator Drugs
6 Global Biosimilar Market
6.1 Historical Market Trends
6.2 Market Segmentation by Region
6.3 Market Outlook
7 GCC Biosimilar Market
7.1 Industry Overview
7.2 Key Industry Developments
7.3 Market Trends
7.3.1 Key Market Indicators
7.3.2 Historical Market Trends
7.3.3 Impact of COVID-19
8 GCC Biosimilar Market Segmentation by Country
8.1 Saudi Arabia
8.1.1 Historical Market Trends
8.1.2 Market Outlook
8.2 United Arab Emirates
8.2.1 Historical Market Trends
8.2.2 Market Outlook
8.3 Qatar
8.3.1 Historical Market Trends
8.3.2 Market Outlook
8.4 Kuwait
8.4.1 Historical Market Trends
8.4.2 Market Outlook
8.5 Oman
8.5.1 Historical Market Trends
8.5.2 Market Outlook
8.6 Bahrain
8.6.1 Historical Market Trends
8.6.2 Market Outlook
9 GCC Biosimilar Market Segmentation by Module
9.1 Infliximab
9.1.1 Historical Market Trends
9.1.2 Market Outlook
9.2 Insulin Glargine
9.2.1 Historical Market Trends
9.2.2 Market Outlook
9.3 Epoetin Alfa
9.3.1 Historical Market Trends
9.3.2 Market Outlook
9.4 Etanercept
9.4.1 Historical Market Trends
9.4.2 Market Outlook
9.5 Filgrastim
9.5.1 Historical Market Trends
9.5.2 Market Outlook
9.6 Somatropin
9.6.1 Historical Market Trends
9.6.2 Market Outlook
9.7 Rituximab
9.7.1 Historical Market Trends
9.7.2 Market Outlook
9.8 Follitropin Alfa
9.8.1 Historical Market Trends
9.8.2 Market Outlook
10 GCC Biosimilar Market Segmentation by Type of Manufacturing
10.1 In-House Manufacturing
10.1.1 Historical Market Trends
10.1.2 Market Outlook
10.2 Contract Manufacturing
10.2.1 Historical Market Trends
10.2.2 Market Outlook
11 GCC Biosimilar Market Segmentation by Indication
11.1 Auto-Immune Diseases
11.1.1 Historical Market Trends
11.1.2 Market Outlook
11.2 Blood Disorder
11.2.1 Historical Market Trends
11.2.2 Market Outlook
11.3 Diabetes
11.3.1 Historical Market Trends
11.3.2 Market Outlook
11.4 Oncology
11.4.1 Historical Market Trends
11.4.2 Market Outlook
11.5 Growth Deficiency
11.5.1 Historical Market Trends
11.5.2 Market Outlook
11.6 Female Infertility
11.6.1 Historical Market Trends
11.6.2 Market Outlook
12 GCC Biosimilar Industry: Market Dynamics
12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats
13 GCC Biosimilar Industry: Value Chain Analysis
13.1 Overview
13.2 Research and Development
13.3 Raw Material Suppliers
13.4 Inbound Logistics
13.5 Production
13.6 Marketing
13.7 Outbound Logistics
13.8 Consumers
14 GCC Biosimilar Industry: Porter’s Five Forces Analysis
14.1 Overview
14.2 Threat of New Entrants
14.3 Threat of Substitutes
14.4 Bargaining Power of Buyers
14.5 Bargaining Power of Suppliers
14.6 Intensity of Rivalry
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Key Success Factors
16 Key Player Profiles
List of Figures
Figure 1: Global: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 2: Global: Biosimilar Market: Segmentation by Region (in %), 2021
Figure 3: Global: Biosimilar Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 4: GCC: Biosimilar Market: Sales Value (in Million US$), 2016-2021
Figure 5: GCC: Biosimilar Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 6: GCC: Biosimilar Market: Segmentation by Country (in %), 2021
Figure 7: GCC: Biosimilar Market: Segmentation by Molecule (in %), 2021
Figure 8: GCC: Biosimilar Market: Segmentation by Type of Manufacturing (in %), 2021
Figure 9: GCC: Biosimilar Market: Segmentation by Indication (in %), 2021
Figure 10: Saudi Arabia: Biosimilar Market: Sales Value (in Million US$), 2016 & 2021
Figure 11: Saudi Arabia: Biosimilar Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 12: United Arab Emirates: Biosimilar Market: Sales Value (in Million US$), 2016 & 2021
Figure 13: United Arab Emirates: Biosimilar Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 14: Qatar: Biosimilar Market: Sales Value (in Million US$), 2016 & 2021
Figure 15: Qatar: Biosimilar Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 16: Kuwait: Biosimilar Market: Sales Value (in Million US$), 2016 & 2021
Figure 17: Kuwait: Biosimilar Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 18: Oman: Biosimilar Market: Sales Value (in Million US$), 2016 & 2021
Figure 19: Oman: Biosimilar Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 20: Bahrain: Biosimilar Market: Sales Value (in Million US$), 2016 & 2021
Figure 21: Bahrain: Biosimilar Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 22: GCC: Biosimilar (Infliximab) Market: Sales Value (in Million US$), 2016 & 2021
Figure 23: GCC: Biosimilar (Infliximab) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 24: GCC: Biosimilar (Insulin Glargine) Market: Sales Value (in Million US$), 2016 & 2021
Figure 25: GCC: Biosimilar (Insulin Glargine) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 26: GCC: Biosimilar (Epoetin Alfa) Market: Sales Value (in Million US$), 2016 & 2021
Figure 27: GCC: Biosimilar (Epoetin Alfa) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 28: GCC: Biosimilar (Etanercept) Market: Sales Value (in Million US$), 2016 & 2021
Figure 29: GCC: Biosimilar (Etanercept) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 30: GCC: Biosimilar (Filgrastim) Market: Sales Value (in Million US$), 2016 & 2021
Figure 31: GCC: Biosimilar (Filgrastim) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 32: GCC: Biosimilar (Somatropin) Market: Sales Value (in Million US$), 2016 & 2021
Figure 33: GCC: Biosimilar (Somatropin) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 34: GCC: Biosimilar (Rituximab) Market: Sales Value (in Million US$), 2016 & 2021
Figure 35: GCC: Biosimilar (Rituximab) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 36: GCC: Biosimilar (Follitropin Alfa) Market: Sales Value (in Million US$), 2016 & 2021
Figure 37: GCC: Biosimilar (Follitropin Alfa) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 38: GCC: Biosimilar (In-house Manufacturing) Market: Sales Value (in Million US$), 2016 & 2021
Figure 39: GCC: Biosimilar (In-house Manufacturing) Market Outlook: Sales Value (in Million US$),2022-2027
Figure 40: GCC: Biosimilar (Contract Manufacturing) Market: Sales Value (in Million US$), 2016 & 2021
Figure 41: GCC: Biosimilar (Contract Manufacturing) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 42: GCC: Biosimilar (Auto-Immune Diseases) Market: Sales Value (in Million US$), 2016 & 2021
Figure 43: GCC: Biosimilar (Auto-Immune Diseases) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 44: GCC: Biosimilar (Blood Disorder) Market: Sales Value (in Million US$), 2016 & 2021
Figure 45: GCC: Biosimilar (Blood Disorder) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 46: GCC: Biosimilar (Diabetes) Market: Sales Value (in Million US$), 2016 & 2021
Figure 47: GCC: Biosimilar (Diabetes) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 48: GCC: Biosimilar (Oncology) Market: Sales Value (in Million US$), 2016 & 2021
Figure 49: GCC: Biosimilar (Oncology) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 50: GCC: Biosimilar (Growth Deficiency) Market: Sales Value (in Million US$), 2016 & 2021
Figure 51: GCC: Biosimilar (Growth Deficiency) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 52: GCC: Biosimilar (Female Infertility) Market: Sales Value (in Million US$), 2016 & 2021
Figure 53: GCC: Biosimilar (Female Infertility) Market Outlook: Sales Value (in Million US$), 2022-2027
Figure 54: GCC: Biosimilar Industry: Market Dynamics
Figure 55: GCC: Biosimilar Industry: Value Chain Analysis
Figure 56: GCC: Biosimilar Market: Porter’s Five Forces Analysis
List of Tables
Table 1: GCC: Biosimilar Market: Key Industry Highlights, 2021 and 2027
Table 2: GCC: Biosimilar Market Outlook: Segmentation by Country (in Million US$), 2022-2027
Table 3: GCC: Biosimilar Market Outlook: Segmentation by Molecule (in Million US$), 2022-2027
Table 4: GCC: Biosimilar Market Outlook: Segmentation by Type of Manufacturing (in Million US$), 2022-2027
Table 5: GCC: Biosimilar Market Outlook: Segmentation by Indication (in Million US$), 2022-2027
Table 6: GCC: Biosimilar Market Structure
Table 7: GCC: Biosimilar Market: Key Players
Special Prices
The maize processing plant project report covers industry performance, manufacturing requirements, project cost, project economics, profit margins, key success and risk factors, expected returns on investment, etc. This report is a must-read for all those who have any kind of stake in the maize indu...
The food processing plant project report covers industry performance, manufacturing requirements, project cost, project economics, profit margins, key success and risk factors, expected returns on investment, etc. This report is a must-read for all those who have any kind of stake in the food indust...
The report provides a techno-commercial roadmap for setting up an oolong tea manufacturing plant. The study covers all the requisite aspects that one needs to know while making a foray into the oolong tea industry.
The GCC casein market was worth US$ XX Billion in 2021, expanding at a CAGR of X% during 2016-2021. Looking forward, the market is projected to grow at a CAGR of around X% during 2022-2027, reaching a value of US$ XX Billion by 2027.
The GCC dog food market was worth US$ XX Billion in 2021, expanding at a CAGR of X% during 2016-2021. Looking forward, the market is projected to grow at a CAGR of around X% during 2022-2027, reaching a value of US$ XX Billion by 2027.